Accelerating G6PD Deficiency Diagnosis with Baebies FINDER for Pre-Discharge, In-Hospital Testing

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a risk factor for kernicterus (i.e., bilirubin-induced neurological damage) in jaundiced newborns and hemolysis following oxidant stress exposure. While the state of New York mandated newborn screening for G6PD deficiency in 2022 for certain clinical presentations, most hospitals are not equipped for such testing, and samples are sent to reference laboratories. Send-out is not optimal for making urgent clinical decisions for treating jaundice and providing results prior to newborn discharge.

At the 2025 Annual Meeting of the Association for Diagnostic Laboratory Medicine (ADLM) in Chicago, we highlighted the Baebies FINDER point-of-care G6PD test (FINDER G6PD), which provides enzyme activity values within 17 minutes using 50 µL of whole blood. Hospital laboratory testing using FINDER G6PD provides results in 4.5 hours compared to 3.1 days, ensuring G6PD diagnosis prior to hospital discharge of newborns. This rapid TAT enables real-time decision-making, allowing timely interventions, including treatment and education for G6PD-deficient newborns.

The prevalence of G6PD deficiency in the population served by New York Presbyterian Hospital – Columbia University Irving Medical Center is high, demonstrating the need for G6PD testing results for patient care. Other patients, such as those being evaluated for possible treatment with medications contraindicated in individuals with G6PD deficiency (e.g., rasburicase), also benefit from more rapid testing results.

Click here to view the poster.

Read Further: 

• 1. Baebies Receives FDA Breakthrough Device Designation for First Point-of-Care Heparin Monitoring Test
  2. Learn more about Digital Microfluidic Technology
  3. Baebies Expands Its Vision: Any Test, Anywhere, Everyone™
  4. Feasibility of PT, aPTT, and Fibrinogen on a Multifunctional Digital Microfluidic Cartridge
  5. Novel Fluorometric Assay for Pediatric Anti-Factor Xa Testing: Minimizing Bilirubin and Hemolysis Interference in Whole Blood